Pfizer Inc. (PFE)

About Pfizer Inc.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

As of November 3, 2026, Pfizer Inc. (PFE) stock edged higher to $30.67, up 0.49% (+$0.15) versus the previous close. On the day, shares have traded between $30.20 and $31.04. That puts PFE near the top of its 52-week range of $23.62 to $31.04. Pfizer Inc. operates in the pharmaceutical preparations space and carries a market capitalization of roughly $173.95 billion, with about 50.82 million shares changing hands.

Latest PFE news

• Pfizer Hikes Guidance On Solid Third Quarter, Names Company Vet As New CFOYahoo Finance· Nov 3, 8:27 AM ET
• Earnings from AMD and Pfizer plus labor market data: What to WatchYahoo Finance· Nov 3, 8:00 AM ETAMDJOLTS
• Pfizer (NYSE:PFE) reports strong Q3 2026, full-year outlook slightly exceeds expectationsYahoo Finance· Nov 3, 7:30 AM ET
• Pfizer increases annual profit forecast amid solid demand for blood thinner drugYahoo Finance· Nov 3, 7:22 AM ET
• Pfizer Finds Life Beyond the Pandemic as Earnings Top EstimatesYahoo Finance· Nov 3, 7:20 AM ET
• Pfizer (PFE) Surpasses Q3 Earnings and Revenue EstimatesYahoo Finance· Nov 3, 7:00 AM ET
• Pfizer Just Gained 12% in a Month to a 52-Week High: Take Profits, or Buy More?tikr.com· Nov 3, 6:59 AM ET
• Pfizer: Q3 Earnings SnapshotYahoo Finance· Nov 3, 6:53 AM ETAP

Source: Yahoo Finance RSS · Updated November 3, 2026

Want PFE headlines, alerts and AI research in one place? Create a free account →

• $PFE Raised guidance is good, but the bigger story is whether new products can keep replacing declining legacy revenue. That's the turnaround I'm watching.

  @mavis12· Nov 3, 8:46 AM ET

• $PFE The COVID hangover is still visible, but the newer portfolio is starting to pull its weight. I'm giving this turnaround more credit.

  @waynemc· Nov 3, 8:45 AM ET· Bullish

• $PFE Revenue was basically flat, so this isn't a clean turnaround yet. But 32% growth in launched and acquired products plus higher guidance is the direction bulls needed.

  @Shanelleme· Nov 3, 8:41 AM ET· Bullish

• $PFE is the valuation high or something. This can’t go up for what reason?

  @TeenageMutantNinjaTrader· Nov 3, 8:32 AM ET

• https://www.cnbc.com/2026/11/03/pfizer-pfe-earnings-q3-2026.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension $PFE Pfizer reported third-quarter results that topped estimates and hiked its full-year outlook, citing its “strong year-to-date performance” and…

  @parcha· Nov 3, 8:18 AM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →